UBS AM
FUSN

UBS AM’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

UBS AM’s Portfolio FUSN Stock Details FUSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-178,155
Closed -$3.11M – 2515
2020
Q2 		$3.11M Buy
+178,155
New +$3.1M ﹤0.01% 1339

Other funds holding FUSN

JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

UBS AM's FUSN Position: Q3 2020 in Review

UBS AM sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q3 2020, closing a stake of 178,155 shares — an estimated $3.11M sold.

UBS AM first reported a position in FUSN in Q2 2020 and held it in 1 quarter. The position peaked at $3.11M in Q2 2020. 29 funds tracked by Wall St. Rank hold FUSN as of Q3 2020.

  • UBS AM reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q3 2020 after selling out during the quarter.
  • UBS AM sold 178,155 Fusion Pharmaceuticals Inc. Common Shares shares in Q3 2020, an estimated $3.11M.
  • UBS AM first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2020 and held it in 1 quarter.
  • UBS AM's Fusion Pharmaceuticals Inc. Common Shares position peaked at $3.11M in Q2 2020.
  • 29 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q3 2020.

Based on UBS AM's 13F filing for Q3 2020, filed 13 Nov 2020.